Freenome is partnering with pharmaceutical companies, integrated health systems, and academic institutions to use its multiomics platform to address cancer’s most pressing challenges.
Together, we're proud to be at the forefront in developing the next generation of early cancer detection blood tests and precision therapies in oncology.
Novel biomarker discovery
New target discovery
Resistance pathway analysis
Response prediction for immuno-oncology and epigenetic modiﬁer